High impact
Simponi (golimumab) (Revised)
Humana·Effective Jan 1, 2026
Humana has revised its Simponi (golimumab) pharmacy coverage policy for Medicare Advantage members, effective January 1, 2026, with a July 22, 2026 revision. The policy establishes prior authorization requirements for Simponi across four indications (Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Ulcerative Colitis) with updated criteria requiring prior failure/contraindication/intolerance to specific biologic therapies before approval.